ESR1 and cancer: Since oestrogen is one of the primary regulators of breast tissue growth by activating ER and resulting growth programs, targeting these pathways as a form of cancer therapy has revolutionized the treatment of ER+ breast cancer, which represent approximately 80% of cases [15–17].